ODN 21158

Cat. No.:	HY-150739
CAS No.:	1964506-31-7
Target:	Toll-like Receptor (TLR)
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

DNA, d(P-thio)(C-C-T-G-G-C-G-G-G-G)

BIOLOGICAL ACTIVITY

Description

ODN 21158 is a potent G-modified TLR3 and TLR9 inhibitor. ODN 21158 shows no cytotoxic. ODN 21158 inhibits IFN-α secretion in a dose dependent manner[1].

In Vitro

ODN 21158 (0.01, 0.1, 1, 10 μM) shows no cytotoxic in human PBMCs[1].

ODN 21158 (0.01, 0.1, 1, 10 μM; 24 h) inhibits IFN-α secretion in a dose dependent manner when stimulated with CpG-ODN 2216 (3 μM) in Human PBMCs[1].

ODN 21158 (0.01, 0.1, 1, 10 μM; 48 h) stimulated with CpG-ODN 2006 (100 nM) failes to inhibit IL-6 release of PBMCs[1].

ODN 21158 (0.01, 0.1, 1, 10 μM; 48 h) inhibits the release of IL-6 when stimulated with imiquimod (5 μg/ml) in human PBMCs [1].

ODN 21158 (0.1, 1, 10 μM; 24 h) inhibits the release of IL-6 in B-cells when stimulated with imiquimod (5 μg/ml) and CpG-ODN 2006 (100 nM)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line:	human PBMCs
Concentration:	0.01, 0.1, 1, 10 μM
Incubation Time:	48 h
Result:	Did not result in increased levels of extracellular LDH and not reduced the intracellular ATP-levels of CpG-ODN 2006-stimulated PBMCs.

REFERENCES

[1]. Römmler F, et al. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells. PLoS One. 2015 Feb 19;10(2):e0116703.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA